CSL is a global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and other hematological conditions, immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. CSL welcomes the opportunity to contribute to this consultation.
CB
CSL Behring
Company · AUS · EU Transparency Register 030031840349-92
6
positions filed
in the 665 files tracked
5
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #291 by legislative files engaged, a count of participation, not a measure of influence.
1.5
declared lobbying FTE
self-declared
€600K+
declared costs / yr (floor)
3
EP accreditations
as declared to the register
2020
in the register since
Declares membership of
- EFPIA - The European Federation of Pharmaceutical Industries and Associations
- EUCOPE - The European Confederation of Pharmaceutical Entrepreneurs
- EuropaBio - The European Association for Bioindustries
- ARM - The Alliance for Regenerative Medicine
- Parliament Magazine
- European Business Summits
- European Policy Centre
- Friends of Europe
- EKHA - European Kidney Health Alliance
- Blood & Beyond
- Transform Alliance
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- CSL
- Head office
- Melbourne, Australia
- EU office
- Mechelen
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track CSL in PolicySpeak: request access →
Work at CSL Behring? so we know who speaks for it.
Their record over time
CSL Behring filed 6 positions between 11 Dec 2020 and 26 Jan 2026, across 5 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2020 · 1 filed2021 · 1 filed2023 · 1 filed2025 · 2 filed2026 · 1 filed
What they argued
CSL Behring welcomes the opportunity to contribute to the evaluation of the public procurement Directive 2014/24/EU. While public procurement of medicinal products is widely used by Member States, the implementation of EU procurement rules varies.
CSL Behring welcomes the overall objectives of the proposed Pharmaceutical Package to enhance the availability and accessibility of medicines, while fostering a future-proof, crisis-resistant life science industry environment.
CSL Behring is strongly committed to bringing valuable, innovative products to market that address unmet medical needs so patients can lead healthy and productive lives. Our strong R&D pipeline utilizes its expertise in plasma fractionation, recombinant technology, and cell and gene therapy.
CSL is a global biotechnology leader with a dynamic portfolio of lifesaving medicines, operating in highly specialized areas that require advanced, complex technologies, broad scientific expertise, and sustained long-term investment.
As a global biopharmaceutical leader in plasma protein therapeutics, CSL Behring supports patient centred policies that allow sustainable and safe access to Plasma Derived Medicinal Products (PDMPs). These therapies are essential for 300,000 European patients to treat a variety of rare, chronic and potentially life-threatening conditions.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put CSL Behring next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 240.
Is this your organization?
Everything on this page comes from CSL Behring’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.